News

The first patient implant in the ARISE II Pivotal Study evaluation of the GORE® Ascending Stent Graft represents a major milestone in the development of endovascular treatment of the ascending aorta.

The Gore RELIEF Clinical Study is evaluating the safety and efficacy of transcatheter closure of patent foramen ovale (PFO) with the GORE® CARDIOFORM Septal Occluder for the relief of migraine headaches.

The Gore VBX FORWARD Clinical Study aims to compare the VBX Stent Graft primary patency to bare metal stenting to evaluate superiority in treating complex iliac occlusive disease.

FIRST U.S. PATIENT ENROLLED IN GORE® VIAFORT VASCULAR STENT ILIOFEMORAL PIVOTAL STUDY

First U.S. patient enrolled in GORE® VIAFORT Vascular Stent pivotal study.

The Gore RELIEF study is evaluating the safety and efficacy of transcatheter closure of patent foramen ovale (PFO) with the GORE® CARDIOFORM Septal Occluder for the relief of migraine headaches.

FLAGSTAFF, Ariz. (October 28, 2022) — W. L. Gore & Associates (Gore) today announced the first implants of its investigational GORE® VIAFORT Vascular Stent as part of the recently initiated GORE VIAFORT Device  Pivotal Clinical Study, (i.e., prospective, multicenter, non-randomized, single-arm study NCT05409976) for the treatment of inferior vena cava (IVC) occlusive disease with or without iliofemoral vein involvement. 

Gore, a global material science company dedicated to transforming industries and improving lives, announce the acquisition of InnAVasc Medical, Inc., a privately held medical technology company focused on advancing care for patients with end stage renal disease who utilize graft circuits for dialysis treatment.

FLAGSTAFF, Ariz. (APRIL 12, 2022) — Gore Medical has received Breakthrough Device designation from the U.S. Food and Drug Administration for the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device). The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The TAMBE Device is the third Breakthrough Device in the company’s aortic endovascular portfolio to date, following the GORE® TAG® Thoracic Branch Endoprosthesis and the GORE® Ascending Stent Graft, two other investigational devices being developed.

FLAGSTAFF, Ariz. (JAN. 19, 2022) — W. L. Gore & Associates (Gore) today announced that the GORE® CARDIOFORM Septal Occluder has achieved 10 years of clinical use, treating patients through clinical studies and commercially in approved indications globally.*,† With more than 50,000 devices sold and zero reported cardiac erosions,‡ (Data on file. July 2011-November 2021; W. L. Gore & Associates, Inc.) this innovative technology from Gore offers physicians a safe option to treat patients with atrial septal defects (ASD) and patent foramen ovale (PFO).